[HTML][HTML] Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome

T Pulingam, T Parumasivam, AM Gazzali… - European Journal of …, 2022 - Elsevier
Antibiotic resistance is a major health concern globally and has been estimated to cause 10
million deaths worldwide by year 2050 if the current trend of inappropriate and excessive …

Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents

E Asín-Prieto, A Rodríguez-Gascón, A Isla - Journal of Infection and …, 2015 - Elsevier
The alarming increase of resistance against multiple currently available antibiotics is leading
to a rapid lose of treatment options against infectious diseases. Since the antibiotic …

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

RL Nation, J Li, O Cars, W Couet… - The Lancet infectious …, 2015 - thelancet.com
In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …

The role of PK/PD analysis in the development and evaluation of antimicrobials

A Rodríguez-Gascón, MÁ Solinís, A Isla - Pharmaceutics, 2021 - mdpi.com
Pharmacokinetic/pharmacodynamic (PK/PD) analysis has proved to be very useful to
establish rational dosage regimens of antimicrobial agents in human and veterinary …

Pharmacokinetic and pharmacodynamic principles of anti-infective dosing

NJ Onufrak, A Forrest, D Gonzalez - Clinical therapeutics, 2016 - Elsevier
Purpose An understanding of the pharmacokinetic (PK) and pharmacodynamic (PD)
principles that determine response to antimicrobial therapy can provide the clinician with …

[HTML][HTML] Machine learning guided early drug discovery of small molecules

N Pillai, A Dasgupta, S Sudsakorn, J Fretland… - Drug discovery today, 2022 - Elsevier
Abstract Machine learning (ML) approaches have been widely adopted within the early
stages of the drug discovery process, particularly within the context of small-molecule drug …

Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward

CB Landersdorfer, RL Nation - Frontiers in Pharmacology, 2021 - frontiersin.org
Within a few years after the first successful clinical use of penicillin, investigations were
conducted in animal infection models to explore a range of factors that were considered …

Dose selection for phase III clinical evaluation of gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections

NE Scangarella-Oman, M Hossain… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Antibiotics are the current standard-of-care treatment for uncomplicated urinary tract
infections (uUTIs). However, increasing rates of bacterial antibiotic resistance necessitate …

Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

M Zhao, AJ Lepak, DR Andes - Bioorganic & medicinal chemistry, 2016 - Elsevier
Animal infection models in the pharmacokinetic/pharmacodynamic (PK/PD) evaluation of
antimicrobial therapy serve an important role in preclinical assessments of new antibiotics …

Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting

Z Sadouki, TD McHugh, R Aarnoutse… - Journal of …, 2021 - academic.oup.com
Objectives This systematic review focuses on the use of the in vitro hollow fibre infection
model (HFIM) for microbial culture. We summarize the direction of the field to date and …